85666-17-7

中文名称 U-63557A

英文名称 U-63557A

CAS 85666-17-7

分子式 C15H10NNaO3

分子量 275.23

MOL 文件 85666-17-7.mol

更新日期 2025/08/15 17:30:15

85666-17-7 结构式

基本信息物理化学性质图谱信息 U-63557A价格(试剂级) 常见问题列表

基本信息

中文别名

化合物 T11339
化合物FUREGRELATE SODIUM

英文别名

U-63557A
furegralate sodium
SODIUM FUREGRELATE
FUREGRELATE SODIUM
FUREGRELATE SODIUM SALT
Furegrelate Sodium (U-63557A)
Sodium 5-(3-pyridinylmethyl)-2-benzofurancarboxylate
5-(3'-Pyridinylmethyl)benzofuran-2-carboxylate sodium
sodium:5-(pyridin-3-ylmethyl)-1-benzofuran-2-carboxylate
5-(3-Pyridylmethyl)benzofuran-2-carboxylic acid sodium salt

物理化学性质

储存条件−20°C

溶解度DMF: >25 mg/ml; DMSO: >21 mg/ml; Ethanol: >14.5 mg/ml; PBS pH 7.2: >16.5 mg/ml

形态白色至类白色结晶固体。

颜色White to light yellow

水溶解性Soluble in water at approximately 15mg/ml

图谱信息

U-63557A(85666-17-7)核磁图(¹HNMR)

U-63557A价格(试剂级)

报价日期	产品编号	产品名称	CAS号	包装	价格
2025/05/22	HY-106080A	U-63557A Furegrelate sodium	85666-17-7	5mg	600元
2025/05/22	HY-106080A	U-63557A Furegrelate sodium	85666-17-7	10 mM * 1 mLin DMSO	660元
2025/05/22	HY-106080A	U-63557A Furegrelate sodium	85666-17-7	10mg	1000元

常见问题列表

生物活性

Furegrelate Sodium (U-63557A) 是一种有效的、口服的、选择性的血栓素合酶 (thromboxane synthase) 抑制剂。Furegrelate Sodium 抑制人血小板微粒体血栓素 A2 (TxA2) 合酶，其 IC50 为 15 nM。Furegrelate Sodium 正在开发作为抗血小板药物。

体内研究

Furegrelate Sodium (U-63557A) (1-5 mg/kg; Oral) prevents blockage of the coronary artery.
Furegrelate Sodium (0.1-5 mg/kg; i.v.) prevents the blockage of stenosed coronary arteries caused platelet aggregation.
Furegrelate Sodium blunts the development of hypoxia-induced pulmonary arterial hypertension (PAH) in an established neonatal piglet model primarily by preserving the structural integrity of the pulmonary vasculature.
Furegrelate also is orally available, has a long half-life of 4.2–5.8 hours in adult humans (compared to several other therapies for PAH including nitric oxide and prostacyclin analogs), and reportedly is highly specific for its target enzyme.

Animal Model:	Mongrel dogs (19-30 kg)
Dosage:	1-5 mg/kg
Administration:	Oral (via a gastric tube)
Result:	Prevented blockage of the coronary artery.